The German company said that the European Patent office revoked Iridex’s MicroPulse patent, which will allow OD-OS to manufacture and market its Navilas laser system in the region. The Navilas system features a computer-assisted laser delivery system and digital documentation, the company said.
OD-OS touted image-guided, pre-planned laser delivery allows for the application of confluent laser patterns without overheating, and that digital documentation allows users to access simplified treatment parameters that can be set in the office.
“We fully respect the effort Iridex Cooperation has put into the clinical development how tissue-sparing, shorter laser pulses can be effective for retinal treatments. With Navilas, we are providing a contact free, easy to use and transparent delivery technique of these laser pulses, which allows standardized treatment protocols. We will work with Navilas users to make microsecond pulse treatment a non-contact, non-damaging but long-lasting treatment in clinical practice, and a viable addition to often chronical injections,” OD-OS managing director Winfried Teiwes said in a press release.